Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,089,844
  • Shares Outstanding, K 143,786
  • Annual Sales, $ 2,607 M
  • Annual Income, $ 404,590 K
  • 60-Month Beta 0.41
  • Price/Sales 8.40
  • Price/Cash Flow 32.30
  • Price/Book 10.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.01
  • Number of Estimates 4
  • High Estimate 1.03
  • Low Estimate 0.96
  • Prior Year 1.00
  • Growth Rate Est. (year over year) +1.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
144.56 +6.27%
on 11/22/19
153.96 -0.21%
on 12/13/19
+8.35 (+5.75%)
since 11/13/19
3-Month
126.26 +21.68%
on 10/23/19
153.96 -0.21%
on 12/13/19
+21.44 (+16.22%)
since 09/13/19
52-Week
90.64 +69.49%
on 01/29/19
153.96 -0.21%
on 12/13/19
+38.30 (+33.21%)
since 12/13/18

Most Recent Stories

More News
Globus Medical Announces Board of Director Addition and Departure

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the appointment of Robert Douglas to the Company's Board of Directors, and the departure of Board member Kurt...

RMD : 153.63 (+0.91%)
GMED : 58.36 (+0.99%)
Neogen's Food Safety Business Thrives on Ergot Alkaloids Test

The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.

NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
NEOG : 68.35 (-1.14%)
HAE : 116.49 (-0.58%)
Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)

Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.

BRKR : 48.87 (-1.43%)
HAE : 116.49 (-0.58%)
RMD : 153.63 (+0.91%)
EYE : 31.53 (-0.72%)
Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

XENT : 21.52 (+0.19%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
Walgreens Extends Deal to Form GPO With Retail Giant Kroger

Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.

RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
WBA : 57.88 (-1.19%)
Here's Why You Should Hold on to Quest Diagnostics Stock Now

Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.

HAE : 116.49 (-0.58%)
NUVA : 75.84 (+2.69%)
RMD : 153.63 (+0.91%)
DGX : 105.20 (-0.11%)
Here's Why You Should Add Omnicell to Your Portfolio Now

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

OMCL : 79.69 (-1.52%)
HAE : 116.49 (-0.58%)
RMD : 153.63 (+0.91%)
NUVA : 75.84 (+2.69%)
Top 5 Companies in the Health Care Equipment Industry with the Best Relative Performance (BDX , ZBH , RMD , BAX , HOLX )

We looked at the Health Care Equipment industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We...

BDX : 268.72 (+1.24%)
RMD : 153.63 (+0.91%)
ZBH : 148.07 (+0.45%)
Are You Looking for a Top Momentum Pick? Why ResMed (RMD) is a Great Choice

Does ResMed (RMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

RMD : 153.63 (+0.91%)
CVS Health Rides on Aetna Prospects, Strong Selling Season

CVS Health's (CVS) 2020 PBM selling season is approaching closure and the 2021 selling season is ongoing.

RMD : 153.63 (+0.91%)
HAE : 116.49 (-0.58%)
CVS : 73.59 (-0.90%)
EYE : 31.53 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RMD with:

Business Summary

ResMed Inc. is a world-leading connected health company with cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions....

See More

Key Turning Points

2nd Resistance Point 155.62
1st Resistance Point 154.62
Last Price 153.63
1st Support Level 151.97
2nd Support Level 150.32

See More

52-Week High 153.96
Last Price 153.63
Fibonacci 61.8% 129.77
Fibonacci 50% 122.30
Fibonacci 38.2% 114.83
52-Week Low 90.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar